The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis.

Drug Safety : an International Journal of Medical Toxicology and Drug Experience
Gerald GartlehnerBradley N Gaynes

Abstract

Second-generation antidepressants dominate the management of patients with major depressive disorder (MDD). Evidence on the general and comparative benefits and harms is still accruing. To systematically review the general and comparative efficacy and safety of duloxetine for the treatment of acute-phase MDD in adults. We conducted a search of MEDLINE, Embase, PsychLit, The Cochrane Library, and the International Pharmaceutical Abstracts from 1980 to July 2009, as well as manually searching reference lists of pertinent review articles and exploring the Center for Drug Evaluation and Research database to identify unpublished research. For efficacy, randomized controlled trials (RCTs) comparing duloxetine with placebo or second-generation antidepressants were included. For safety, both experimental and observational studies were eligible. Abstracts and full-text articles were independently reviewed by two people, one investigator extracted relevant data, and a senior reviewer checked data for completeness and accuracy. We included 36 experimental and observational studies and, where sufficient data were available, meta-analyses of RCTs were conducted. Findings indicated that duloxetine is an effective treatment option for acute-p...Continue Reading

References

Jan 1, 1994·International Clinical Psychopharmacology·S A MontgomeryD Nutt
Oct 1, 1996·Current Biology : CB·A Murray
Apr 18, 2001·American Journal of Preventive Medicine·R P HarrisUNKNOWN Methods Work Group, Third US Preventive Services Task Force
Apr 3, 2002·The Journal of Clinical Psychiatry·David J GoldsteinMark A Demitrack
May 10, 2002·The Journal of Clinical Psychiatry·Michael J DetkeMark A Demitrack
Oct 24, 2002·Journal of Psychiatric Research·Michael J DetkeMark A Demitrack
Sep 23, 2003·Health Technology Assessment : HTA·J J DeeksUNKNOWN European Carotid Surgery Trial Collaborative Group
Dec 9, 2003·The Journal of Clinical Psychiatry·Joel RaskinMargaret B Ferguson
Jan 20, 2004·The Journal of Clinical Psychiatry·Paul E GreenbergPatricia K Corey-Lisle
May 25, 2004·Primary Care Companion to the Journal of Clinical Psychiatry·Craig H. MallinckrodtPierre V. Tran
Jun 24, 2004·The Australian and New Zealand Journal of Psychiatry·Peter Ellis, UNKNOWN Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression
Jul 3, 2004·Journal of Clinical Psychopharmacology·David J GoldsteinMark A Demitrack
Oct 27, 2004·Journal of Psychiatric Research·Stephen K BrannanAlan F Schatzberg
Dec 14, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michael J DetkeIstvan Bitter
Mar 2, 2005·Journal of Clinical Psychopharmacology·Michael E ThaseMichael J Detke
May 16, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·D G S PerahiaM J Detke
May 17, 2006·International Journal of Clinical Practice·D G S PerahiaA Tylee
Aug 1, 2006·International Clinical Psychopharmacology·John CooksonDaniel K Kajdasz
Nov 18, 2006·Journal of Clinical Psychopharmacology·Nayan AcharyaRoss J Baldessarini
May 3, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joachim WernickeFujun Wang
Jun 15, 2007·Current Medical Research and Opinion·Teresa A PigottMadelaine M Wohlreich
Jun 26, 2007·International Journal of Clinical Practice·T N WiseJ Raskin
Jul 11, 2007·Depression and Anxiety·David L DunnerMadelaine Wohlreich
Oct 6, 2007·International Clinical Psychopharmacology·Richard C SheltonMichael J Detke
Jan 22, 2008·Journal of Clinical Psychopharmacology·Joel RaskinCornelius Katona
Sep 2, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gerald GartlehnerKathleen N Lohr

❮ Previous
Next ❯

Citations

Jun 13, 2012·European Journal of Clinical Pharmacology·Linda HärmarkKees van Grootheest
Mar 2, 2011·Archives of Women's Mental Health·Philip M BoyceKenneth F Ilett
Jul 23, 2013·Clinical Drug Investigation·Cesario BellantuonoChiara Lucarelli
Apr 7, 2010·Drug Design, Development and Therapy·Trevor R Norman, James S Olver
May 7, 2011·Expert Opinion on Drug Safety·Istvan BitterPal Czobor
Dec 14, 2011·The Cochrane Database of Systematic Reviews·Kylie ThalerGerald Gartlehner
Oct 22, 2011·Expert Review of Neurotherapeutics·Lanny BochslerTrevor R Norman
Oct 19, 2012·The Cochrane Database of Systematic Reviews·Andrea CiprianiCorrado Barbui
Jul 15, 2018·The Journal of Pharmacology and Experimental Therapeutics·Carmen NanclaresAntonio G García
Jul 12, 2011·The International Journal of Eating Disorders·Anna I GuerdjikovaJames I Hudson
Nov 4, 2015·Basic & Clinical Pharmacology & Toxicology·Himanshu NaikJohan Areberg
Aug 4, 2019·Regional Anesthesia and Pain Medicine·Andrés Zorrilla-VacaMichael Conrad Grant
Sep 23, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Sakina J Rizvi, Sidney H Kennedy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved